Eli Lilly sues compounders and medical spas over sales of unapproved copycats of its diabetes blockbuster Mounjaro

Eli Lil­ly on Tues­day sued 10 med­ical spas, well­ness cen­ters and com­pound­ing phar­ma­cies in Flori­da, Geor­gia, Ari­zona, Min­neso­ta, Utah and Texas for sell­ing un­ap­proved and com­pound­ed ver­sions of its block­buster type 2 di­a­betes drug Moun­jaro (tirzepatide).

Lil­ly is ask­ing the de­fen­dants, sev­er­al of whom use an unau­tho­rized Moun­jaro trade­mark on their web­sites, to stop pro­vid­ing drugs in vi­o­la­tion of con­sumer pro­tec­tion laws. The com­pa­ny notes height­ened safe­ty con­cerns, say­ing some of these com­pa­nies promise their pa­tients that the drugs of­fer the same safe­ty pro­file and clin­i­cal ben­e­fits as Moun­jaro when they’re ac­tu­al­ly com­pound­ed ver­sions that don’t ad­here to the same FDA reg­u­la­tions as ful­ly ap­proved prod­ucts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.